MA49503A - Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant - Google Patents

Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant

Info

Publication number
MA49503A
MA49503A MA049503A MA49503A MA49503A MA 49503 A MA49503 A MA 49503A MA 049503 A MA049503 A MA 049503A MA 49503 A MA49503 A MA 49503A MA 49503 A MA49503 A MA 49503A
Authority
MA
Morocco
Prior art keywords
immunotherapy
new
lymphocyte receptors
lymphocyte
receptors
Prior art date
Application number
MA049503A
Other languages
English (en)
Inventor
Leonie Alten
Sebastian Bunk
Dominik Maurer
Claudia Wagner
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA49503A publication Critical patent/MA49503A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632T-cell receptors [TCR]; antibody T-cell receptor constructs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA049503A 2017-06-30 2018-06-28 Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant MA49503A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527844P 2017-06-30 2017-06-30
DE102017114737.3A DE102017114737A1 (de) 2017-06-30 2017-06-30 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie

Publications (1)

Publication Number Publication Date
MA49503A true MA49503A (fr) 2020-05-06

Family

ID=64662173

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049503A MA49503A (fr) 2017-06-30 2018-06-28 Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant

Country Status (20)

Country Link
US (4) US10590194B2 (fr)
EP (1) EP3645573A1 (fr)
JP (1) JP7235316B2 (fr)
KR (1) KR20200023288A (fr)
CN (1) CN110753705A (fr)
AR (1) AR112604A1 (fr)
AU (1) AU2018293322A1 (fr)
BR (1) BR112019025323A2 (fr)
CA (1) CA3067757A1 (fr)
CL (1) CL2019003885A1 (fr)
CO (1) CO2020000357A2 (fr)
CR (1) CR20190594A (fr)
DE (1) DE102017114737A1 (fr)
IL (1) IL271751A (fr)
MA (1) MA49503A (fr)
MX (1) MX2019015742A (fr)
PE (1) PE20200337A1 (fr)
SG (1) SG11201911437VA (fr)
TW (1) TWI727182B (fr)
WO (1) WO2019002444A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
TW202110875A (zh) 2019-05-27 2021-03-16 美商英麥提克斯股份有限公司 病毒載體及其在授受性細胞療法之應用
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术(广东)有限公司 一种识别ssx2的高亲和力t细胞受体
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス,アイエヌシー. がんおよび関連する悪性腫瘍の治療のためにt細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
CA3203118A1 (fr) 2020-12-31 2022-07-07 Gagan BAJWA Polypeptides cd8, compositions et leurs methodes d'utilisation
WO2022233957A1 (fr) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Polypeptides de liaison à l'antigène bma031
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
WO2023081461A1 (fr) 2021-11-08 2023-05-11 Immatics US, Inc. Procédés de génération de sphéroïdes cellulaires
WO2023212697A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212691A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2000006732A2 (fr) * 1998-07-31 2000-02-10 Diagnostic Products Corporation Polynucleotide codant un auto-antigene associe a l'endometriose
CA2398136A1 (fr) 2000-02-08 2001-08-16 The Penn State Research Foundation Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
US10093977B2 (en) * 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
US10550154B2 (en) * 2012-08-08 2020-02-04 Daiichi Sankyo Company, Limited Peptide library and use thereof
EP3572423B1 (fr) * 2013-07-15 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Récepteurs de lymphocytes t anti-papillomavirus humain 16 e6
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
MX2017005925A (es) * 2014-11-05 2017-11-08 Genentech Inc Metodos de producción de proteínas de cadena doble en bacterias.
EP3156067A1 (fr) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin Récepteurs de lymphocytes t hpv à avidité élevée
GB201520597D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520567D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers

Also Published As

Publication number Publication date
US20210388079A1 (en) 2021-12-16
CR20190594A (es) 2020-03-02
AR112604A1 (es) 2019-11-20
US10590194B2 (en) 2020-03-17
US20200140540A1 (en) 2020-05-07
CA3067757A1 (fr) 2019-01-03
TWI727182B (zh) 2021-05-11
SG11201911437VA (en) 2020-01-30
CL2019003885A1 (es) 2020-05-29
DE102017114737A1 (de) 2019-01-03
JP7235316B2 (ja) 2023-03-08
AU2018293322A1 (en) 2020-01-16
US20190256590A1 (en) 2019-08-22
JP2020529830A (ja) 2020-10-15
KR20200023288A (ko) 2020-03-04
EP3645573A1 (fr) 2020-05-06
US20190002556A1 (en) 2019-01-03
BR112019025323A2 (pt) 2020-06-23
US10723796B2 (en) 2020-07-28
CN110753705A (zh) 2020-02-04
MX2019015742A (es) 2020-02-20
US11111294B2 (en) 2021-09-07
CO2020000357A2 (es) 2020-01-31
WO2019002444A1 (fr) 2019-01-03
IL271751A (en) 2020-02-27
WO2019002444A9 (fr) 2019-03-14
TW201904989A (zh) 2019-02-01
PE20200337A1 (es) 2020-02-14

Similar Documents

Publication Publication Date Title
MA49236A (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
MA49503A (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
MA45976A (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
MA44608A (fr) Récepteurs des lymphocytes t
MA47359A (fr) Récepteurs de lymphocytes t à appariement amélioré
MA52193A (fr) Récepteurs de lymphocytes t et cellules modifiées les exprimant
DK4219542T3 (da) T-cellereceptorer
DK3455257T3 (da) Anti-pd-l1-antistoffer
DK3443096T5 (da) Sammensætninger og fremgangsmåder til selektiv ekspression af kimære antigenreceptorer
DK3180447T3 (da) Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
DK3494133T3 (da) Anti-kras-g12d-t-cellereceptorer
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3440102T3 (da) T-cellereceptorer
DK3186284T3 (da) Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
CL2016002375A1 (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina y métodos que usan los mismos
CL2015003406A1 (es) Anticuerpos receptores de antitransferina y métodos de uso campo de la invención
MA50651A (fr) Récepteurs de lymphocytes t reconnaissant p53 mutée
DK3293202T3 (da) Anti human interleukin-1 receptor accessory protein (il1rap) antibodies and uses thereof
WO2018075820A3 (fr) Récepteurs antigéniques chimériques hétérodimérisables à base de céréblon
DK3708579T3 (da) Claudin-6-specifikke immunreceptorer og t-celleepitoper
DK3597663T3 (da) Kimære antigenreceptorer af anti-cd70
HK1255312A1 (zh) 抗原受體及其用途
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
DK3233903T3 (da) Kimære antigenreceptorer og anvendelsesfremgangsmåder
IL275040A (en) T cells containing two chimeric receptors for different antigens and their use